Zeria To Submit NDA For Functional Dyspepsia Drug In Japan
This article was originally published in PharmAsia News
Executive SummaryTokyo-based Zeria Pharmaceutical announced positive results of Japanese Phase III study of Z-338 (acotiamide) for functional dyspepsia
You may also be interested in...
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.